WaveMan
WaveMan · Company
OTLK · Outlook Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

OTLK Outlook Therapeutics (OTLK) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001649989
Quote by TradingView
Cluster · 6 insiders
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
49
13F, latest reported quarter

What the filings say about OTLK

Insiders, 180 days
+$7.9M net bought
6 buyers

Outlook Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Outlook Therapeutics, Inc. insiders bought a net $7.9M of stock across 42 Form 4 purchases and sales, with 6 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
KENYON LAWRENCE A
Chief Financial Officer
BUY
2026-08-14 SEC
101,010
-
-23.7%
Jahr Robert Charles
Chief Executive Officer
BUY
2026-08-14 SEC
151,515
-
-23.7%
Sukhtian Ghiath M.
Director
BUY
2026-08-14 SECtraded 2026-08-12
2,525,252
$2.5M
-23.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 29, 2021.
  • The trade is 10.3% of the 24,617,320 shares held after it.
  • 1 other insider bought within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sukhtian Ghiath M. bought about $2.5M of OTLK on Aug 12, 2026; 1 other insider bought within 30 days and 49 funds added in the latest 13F quarter.
Sukhtian Faisal Ghiath
Director
BUY
2026-07-29 SEC
95,398
$100.0K
-50.7%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on May 27, 2026.
  • +9.2% median (+4.7% mean) 90-day return after 3 previous buys.
  • The trade is 43.2% of the 220,972 shares held after it.
  • 1 other insider bought within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sukhtian Faisal Ghiath bought about $100.0K of OTLK on Jul 29, 2026; 1 other insider bought within 30 days and 49 funds added in the latest 13F quarter.
Haddadin Yezan Munther
Director
BUY
2026-06-03 SECtraded 2026-06-02
29,000
$24.1K
-35.5%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on May 26, 2026.
  • -15.9% median (+0.2% mean) 90-day return after 5 previous buys.
  • The trade is 43.8% of the 66,167 shares held after it.
  • 4 other insiders bought within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Haddadin Yezan Munther bought about $24.1K of OTLK on Jun 2, 2026; 4 other insiders bought within 30 days and 49 funds added in the latest 13F quarter.
42 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 37 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$7.9M over 180 days
+$2.5M over 90 days · +$7.5M of it by a 10%+ holder
more than 95% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
49 funds bought in last quarter
below 54% of Pharma & Biotech
Revenue
-82.6% year over year
below 88% of Pharma & Biotech
Margin
-4416.2% net margin
below 96% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
18.5% of the float short (float per yahoo 2026-10-27) · 6.8 days to cover · settled 2026-10-15
more than 81% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch OTLK

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-60.5%12M
-85%-27%+32%+90%2025-102025-122026-022026-042026-062026-082026-10 2026-05-28 · GMS Ventures & Investments bought $5.0M2026-08-12 · Sukhtian Ghiath M. bought $2.5M2026-05-26 · HILZINGER KURT J bought $176.0K2026-07-29 · Sukhtian Faisal Ghiath bought $100.0K2026-05-27 · Sukhtian Faisal Ghiath bought $50.1K2026-06-02 · Haddadin Yezan Munther bought $24.1K2026-05-26 · Haddadin Yezan Munther bought $15.0K2026-05-26 · THURMAN RANDY H bought $2.1K2026-08-14 · KENYON LAWRENCE A bought -2026-08-14 · Jahr Robert Charles bought -
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns OTLK: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
4,376,872 sh
$7.0M
PERCEPTIVE ADVISORS LLC
3,139,216 sh
$5.0M
MARSHALL WACE, LLP
1,987,578 sh
$3.2M
BlackRock, Inc.
1,668,579 sh
$2.7M
JANE STREET GROUP, LLC
1,425,270 sh
$2.3M

Congress trades in OTLK

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

OTLK planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

OTLK mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
VANGUARD EXTENDED MARKET INDEX FUND
$2.0M position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$279.4K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$4.9M position · as of 2026-06-30
0.0%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND
$73.3K position · as of 2026-06-30
0.0%
Knights of Columbus U.S. ALL CAP INDEX FUND
$589 position · as of 2026-07-31
0.0%
VANGUARD BALANCED INDEX FUND
$47.1K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
5
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
6 insiders reported buying shares.
The record shows a net $7.9M bought by insiders over 180 days, 49 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

OTLK financials

Revenue growth
-82.6%
XBRL, annual
Net margin
-4416.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$56.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.06x
TTM operating cash flow over long-term 2020-06-30 (73 months older than the period end) plus current 2020-06-30 (73 months older than the period end)
Return on equity
n/a
average equity is zero or negative
Return on assets
-251.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.1B
market value at close 2026-10-26 on 2026-08-14 shares, plus long-term 2020-06-30 (73 months older than the period end) plus current 2020-06-30 (73 months older than the period end), minus cash 2026-06-30
FCF yield
-45.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-092024-092023-092022-09
Revenue$1.4Mn/an/an/a
Gross profit$57.2Kn/an/an/a
Operating income-$67.1M-$71.7M-$53.1M-$63.1M
Net income-$62.4M-$75.4M-$59.0M-$66.1M
EPS (diluted)-1.79-4.06-4.72-0.31
Operating cash flow-$51.8M-$68.8M-$43.0M-$56.7M
Cash$8.1M$14.9M$23.4M$17.4M
SEC XBRL, fiscal years, as known on 2026-10-28

OTLK Stock Sonar score 5/7 axes

Find similar shapesCompare

OTLK ranks highest on insider conviction (96th percentile) and financial health (69th), and lowest on growth (12th), among Pharma & Biotech peers.

HealthGrowthInsidersInstitutionsRisk
Financial health
69
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.06x · 69 pct, sector of 371
Growth
12
Inputs
  • Revenue growth, YoY-82.6% · 12 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
96
Inputs
  • Net Form 4 buying (codes P and S), 180d$7.9M · 95 pct, sector of 429
  • Insider buyers, 180d6 · 98 pct, sector of 438
Institutional and government
46
Inputs
  • Funds adding, latest quarter49 · 46 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
17
Inputs
  • Short interest, % of float+18.5% · 17 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Profitability, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

OTLK filings, in plain words

Are Outlook Therapeutics insiders buying or selling OTLK?

In the 180 days to 2026-10-28, Outlook Therapeutics insiders were net buyers, a net $7.9M across purchases and sales reported on Form 4, by 6 buyers.

Read the full summary

In the 180 days to 2026-10-28, Outlook Therapeutics insiders were net buyers of OTLK, a net $7.9M across purchases and sales reported on Form 4 by 6 buyers. Most of that figure, $7.5M, came from a holder of 10% or more rather than an officer or director. 6 insiders reported purchases in that window. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies